Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling

Jin,Fangchun; Qu,Xinhua; Fan,Qiming; Wang,Lei; Tang,Tingting; Hao,Yongqiang; Dai,Kerong

doi:10.3892/mmr.2013.1698

Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling

Authors:
- Fangchun Jin
- Xinhua Qu
- Qiming Fan
- Lei Wang
- Tingting Tang
- Yongqiang Hao
- Kerong Dai
View Affiliations

Affiliations: Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, P.R. China
Published online on: September 23, 2013 https://doi.org/10.3892/mmr.2013.1698
Pages: 1486-1492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone is a major site of metastasis for several types of malignant tumor. Specific interactions between tumor cells and the bone microenvironment contribute to the tendency of tumors to metastasize to bone. Furthermore, Wnt5a participates in the progression of several types of malignant tumor. This study investigates the role of Wnt5a in the migration of the prostate cancer (PCa) cell line PC3 toward bone marrow stromal cell (BMSC)‑conditioned medium (CM). The expression of 22 genes associated with bone metastasis was measured in three PCa cell lines (LNCaP, PC3 and DU145). Subsequently, the proliferation and migration capacities of PC3 cells treated either with small interfering RNA (siRNA) against Wnt5a or with recombinant mouse (rm) Wnt5a were analyzed with alamarBlue and transwell assays. BMSC‑CM was collected to evaluate its effect on PC3 cell migration. Also, the expression of Wnt5a in BMSCs was knocked down prior to collection of the CM to evaluate its effects on the migration of PC3 cells. Significantly higher levels of Wnt5a mRNA expression were identified in the PC3 cells, compared with those in LNCaP and DU145 cells. Silencing Wnt5a expression with siRNA reduced the migration capacity of PC3 cells by 50%. The addition of rmWnt5a improved the migration capacity of PC3 cells in a concentration‑dependent manner. PC3 cells preferred to migrate toward BMSC‑CM than toward the control. CM from Wnt5a siRNA‑treated BMSCs significantly reduced PC3 cell migration. Wnt5a promotes PC3 cell migration toward BMSC‑CM, indicating that Wnt5a is a potential therapeutic target for the treatment of advanced PCa.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Suva LJ, Washam C, Nicholas RW and Griffin RJ: Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 7:208–218. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bickels J, Dadia S and Lidar Z: Surgical management of metastatic bone disease. J Bone Joint Surg Am. 91:1503–1516. 2009. View Article : Google Scholar : PubMed/NCBI
4	Santini D, Galluzzo S, Zoccoli A, et al: New molecular targets in bone metastases. Cancer Treat Rev. 36(Suppl 3): S6–S10. 2010. View Article : Google Scholar
5	Jin JK, Dayyani F and Gallick GE: Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI
6	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
7	Jenei V, Sherwood V, Howlin J, et al: A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci USA. 106:19473–19478. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bitler BG, Nicodemus JP, Li H, et al: Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 71:6184–6194. 2011. View Article : Google Scholar : PubMed/NCBI
9	Weeraratna AT, Jiang Y, Hostetter G, et al: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 1:279–288. 2002. View Article : Google Scholar : PubMed/NCBI
10	Wang Q, Symes AJ, Kane CA, et al: A novel role for Wnt/Ca²⁺ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One. 5:e104562010.PubMed/NCBI
11	Li D, Dai K and Tang T: Effects of dextran on proliferation and osteogenic differentiation of human bone marrow-derived mesenchymal stromal cells. Cytotherapy. 10:587–596. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
13	Kikuchi A, Yamamoto H, Sato A and Matsumoto S: Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf). 204:17–33. 2012. View Article : Google Scholar : PubMed/NCBI
14	Witze ES, Litman ES, Argast GM, Moon RT and Ahn NG: Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science. 320:365–369. 2008. View Article : Google Scholar : PubMed/NCBI
15	Roarty K and Serra R: Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth. Development. 134:3929–3939. 2007. View Article : Google Scholar : PubMed/NCBI
16	McDonald S and Silver A: The opposing roles of Wnt-5a in cancer. Br J Cancer. 101:209–214. 2009. View Article : Google Scholar : PubMed/NCBI
17	Da Forno PD, Pringle JH, Hutchinson P, et al: WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res. 14:5825–5832. 2008.PubMed/NCBI
18	O’Connell MP, Fiori JL, Xu M, et al: The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 29:34–44. 2010.PubMed/NCBI
19	Kurayoshi M, Oue N, Yamamoto H, et al: Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66:10439–10448. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ripka S, König A, Buchholz M, et al: WNT5A-target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis. 28:1178–1187. 2007. View Article : Google Scholar : PubMed/NCBI
21	Hanaki H, Yamamoto H, Sakane H, et al: An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther. 11:298–307. 2012. View Article : Google Scholar : PubMed/NCBI
22	Peng C, Zhang X, Yu H, Wu D and Zheng J: Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer. 21:280–288. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kamino M, Kishida M, Kibe T, et al: Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2. Cancer Sci. 102:540–548. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ying J, Li H, Yu J, et al: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res. 14:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
25	Blanc E, Roux GL, Bénard J and Raguénez G: Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene. 24:1277–1283. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jönsson M, Dejmek J, Bendahl PO and Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 62:409–416. 2002.PubMed/NCBI
27	Deng G, Li ZQ, Zhao C, et al: WNT5A expression is regulated by the status of its promoter methylation in leukaemia and can inhibit leukemic cell malignant proliferation. Oncol Rep. 25:367–376. 2011.PubMed/NCBI
28	Syed Khaja AS, Helczynski L, Edsjö A, et al: Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One. 6:e265392011.PubMed/NCBI
29	Yamamoto H, Oue N, Sato A, et al: Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene. 29:2036–2046. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhang S, Wang J, Bilen MA, Lin SH, Stupp SI and Satcher RL: Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis. 26:993–1004. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zhau HE, He H, Wang CY, et al: Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res. 17:2159–2169. 2011. View Article : Google Scholar : PubMed/NCBI
32	Hart CA, Brown M, Bagley S, Sharrard M and Clarke NW: Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer. 92:503–512. 2005.PubMed/NCBI
33	van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC and van der Pluijm G: Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol. 179:2559–2568. 2011.
34	Mochizuki H, Matsubara A, Teishima J, et al: Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun. 320:656–663. 2004. View Article : Google Scholar
35	Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS and McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62:1832–1837. 2002.PubMed/NCBI